ArticleFrontiers in cardiovascular medicine2026
The predictive value of the C-reactive protein-stress hyperglycemia ratio for in-hospital major adverse cardiovascular events in patients with ST-segment elevation myocardial infarction.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High-sensitivity C-reactive protein (hs-CRP) and stress hyperglycemia ratio (SHR) are recognized as predictors of major adverse cardiovascular events (MACE) in patients with ST-segment elevation myocardial infarction (STEMI). To comprehensively evaluate their combined contribution, we proposed the high-sensitivity C-reactive protein-stress hyperglycemia ratio (CSR). This study aims to assess the predictive value of CSR for in-hospital MACE in STEMI patients. Methods: This single-center retrospective analysis enrolled patients with STEMI admitted to the Third Affiliated Hospital of Anhui Medical University between October 1, 2021 and June 1, 2025. Based on the incidence of in-hospital major adverse cardiovascular events (MACE), the patients were categorized into MACE and non-MACE groups. Univariate and multivariate logistic regression analyses, restricted cubic spline (RCS) curves, receiver operating characteristic (ROC) curve analysis, and subgroup analyses were conducted to examine the relationship between CSR and in-hospital MACE in STEMI patients. Results: A total of 246 patients were enrolled, with 56 assigned to the MACE group and 190 to the non-MACE group. The CSR value was significantly higher in the MACE group than in the non-MACE group ( Conclusion: CSR is a reliable biomarker for predicting in-hospital MACE in STEMI patients. It may help optimize early risk stratification and potentially improve prognosis in high-risk patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.